Drug Trial Radar · NCT01167712
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
692
Actual
Start
Oct 12, 2010
Primary completion
Dec 1, 2015
Study completion Sep 14, 2026
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- NRG Oncology
- First posted
- Jul 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a type of drug called a monoclonal antibody and blocks tumor growth by stopping the growth of blood vessels that tumors need to grow. It is not yet known whether giving paclitaxel with combination chemotherapy once every three weeks is more effective than giving paclitaxel once a week in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.
Conditions
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Ovarian Brenner Tumor
- Ovarian Clear Cell Adenocarcinofibroma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Adenocarcinoma
- Ovarian Transitional Cell Carcinoma
- Ovarian Undifferentiated Carcinoma
- Primary Peritoneal Serous Adenocarcinoma
- Stage IIA Fallopian Tube Cancer AJCC v6 and v7
- Stage IIA Ovarian Cancer AJCC V6 and v7
- Stage IIB Fallopian Tube Cancer AJCC v6 and v7
- Stage IIB Ovarian Cancer AJCC v6 and v7
- Stage IIC Fallopian Tube Cancer AJCC v6 and v7
- Stage IIC Ovarian Cancer AJCC v6 and v7
- Stage IIIA Fallopian Tube Cancer AJCC v7
- Stage IIIA Ovarian Cancer AJCC v6 and v7
- Stage IIIA Primary Peritoneal Cancer AJCC v7
- Stage IIIB Fallopian Tube Cancer AJCC v7
- Stage IIIB Ovarian Cancer AJCC v6 and v7
- Stage IIIB Primary Peritoneal Cancer AJCC v7
- Stage IIIC Fallopian Tube Cancer AJCC v7
- Stage IIIC Ovarian Cancer AJCC v6 and v7
- Stage IIIC Primary Peritoneal Cancer AJCC v7
- Stage IV Fallopian Tube Cancer AJCC v6 and v7
- Stage IV Ovarian Cancer AJCC v6 and v7
- Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
BevacizumabBiological
Given IV
CarboplatinDrug
Given IV
Computed TomographyProcedure
Correlative studies
PaclitaxelDrug
Given IV
Therapeutic Conventional SurgeryProcedure
Undergo surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free SurvivalTime frame: The timeframe is from enrollment onto the study up to 3 years following enrollment.
Locations
563 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Providence Alaska Medical Center
Anchorage, Alaska
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
East Bay Radiation Oncology Center
Castro Valley, California
Valley Medical Oncology Consultants-Castro Valley
Castro Valley, California
John Muir Medical Center-Concord
Concord, California
Bay Area Breast Surgeons Inc
Emeryville, California
Kaiser Permanente-Fremont
Fremont, California
Valley Medical Oncology Consultants-Fremont
Fremont, California
Kaiser Permanente-Fresno
Fresno, California
Marin Cancer Care Inc
Greenbrae, California
UC San Diego Moores Cancer Center
La Jolla, California
Long Beach Memorial Medical Center-Todd Cancer Institute
Long Beach, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California
Contra Costa Regional Medical Center
Martinez, California
El Camino Hospital
Mountain View, California
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California
Wilma Chan Highland Hospital
Oakland, California
Alta Bates Summit Medical Center - Summit Campus
Oakland, California
Bay Area Tumor Institute
Oakland, California
Hematology and Oncology Associates-Oakland
Oakland, California
Tom K Lee Inc
Oakland, California
Kaiser Permanente Oakland-Broadway
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
Kaiser Permanente-Rancho Cordova Cancer Center
Rancho Cordova, California
Kaiser Permanente-Redwood City
Redwood City, California
Kaiser Permanente-Richmond
Richmond, California
Rohnert Park Cancer Center
Rohnert Park, California
Showing 40 of 563 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.